FDA Approves Third Biosimilar to Trastuzumab

On January 18, the FDA approved trastuzumab-dttb (Ontruzant, Samsung Bioepis), a biosimilar to trastuzumab (Herceptin), for the treatment of patients with HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.

Read the OncLive news coverage here.

Posted 1/18/19